OFG
TARS icon

OmniStar Financial Group’s Tarsus Pharmaceuticals TARS Stock Holding History

OmniStar Financial Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,367
Closed -$430K – 123
2025
Q1 		$430K Buy
+8,367
New +$414K 0.34% 87

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

OmniStar Financial Group's TARS Position: Q2 2025 in Review

OmniStar Financial Group sold out of Tarsus Pharmaceuticals (TARS) in Q2 2025, closing a stake of 8,367 shares — an estimated $430K sold.

OmniStar Financial Group first reported a position in TARS in Q1 2025 and held it in 1 quarter. The position peaked at $430K in Q1 2025. 205 funds tracked by Wall St. Rank hold TARS as of Q2 2025.

  • OmniStar Financial Group reported no remaining Tarsus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • OmniStar Financial Group sold 8,367 Tarsus Pharmaceuticals shares in Q2 2025, an estimated $430K.
  • OmniStar Financial Group first reported a position in Tarsus Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • OmniStar Financial Group's Tarsus Pharmaceuticals position peaked at $430K in Q1 2025.
  • 205 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2025.

Based on OmniStar Financial Group's 13F filing for Q2 2025, filed 8 Aug 2025.